Sunovion Pharmaceuticals said that a phase 2 study evaluating SEP-4199 as the treatment of major depressive episodes associated with bipolar I disorder (bipolar I depression) failed to meet its primary endpoint.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,